Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.

Published in: Journal of gynecologic oncology (2024)

For patients with advanced or recurrent EC, the combination of atezolizumab and chemotherapy may not prove cost-effective. However, administering atezolizumab for a limited period of maximum 2 years could improve cost-effectiveness in dMMR EC.

Keyphrases

endometrial cancer
locally advanced
squamous cell carcinoma
chemotherapy induced
rectal cancer
radiation therapy